Xinhui Lu, Yan Huang, Mingqian Zhou, Yixuan Guo, Yihan Zhou, Rongyun Wang, Wumeng Jin, Chengping Wen, Yun Zhang, Yujun Tang
Clinical studies indicated that Serum Amyloid A (SAA) might be a promising biomarker for forecasting the activity, severity, and adverse prognosis of systemic lupus erythematosus (SLE). Simultaneously, a positive correlation has been observed between macrophages, Th17 cells, and SLE disease activity, with both these immune cells being affected by SAA. Presently, the relationship between SAA and the aforementioned immune cell types in SLE remains to be elucidated. To discern the immune cell type most closely associated with SAA, we undertook a single-cell RNA sequencing data analysis via the GEO database...
December 29, 2023: International Immunopharmacology